ReviewThe Journal of infectious diseases2017
The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace.
Review in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 864 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
864 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,509 citations in OpenAlex.
- Carbapenem resistance and associated resistance genes in enterobacteriaceae and non-enterobacteriaceae in India: A systematic review and meta-analysis.The Indian journal of medical research · 2026Pooled it
- Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis.Antimicrobial agents and chemotherapy · 2026Pooled it
- Impact of microplastics on the human gut microbiome: a systematic review of microbial composition, diversity, and metabolic disruptions.BMC gastroenterology · 2025Pooled it
- Systematic review and meta-analysis on the carbapenem-resistant hypervirulent Klebsiella pneumoniae isolates.BMC pharmacology & toxicology · 2025Pooled it
- Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Pharmacokinetics, safety, and tolerability of nacubactam (OP0595) after intravenous infusion: a randomized, double-blind, placebo-controlled phase I clinical trial in healthy Chinese male subjects.Clinical and experimental medicine · 2025Trial
- Pharmacokinetics and safety of single and repeat doses of ceftibuten in healthy participants: a phase 1 dose escalation study.Antimicrobial agents and chemotherapy · 2025Trial
- Carbapenemase-producingEmerging microbes & infections · 2026Article
- Clinical burden and outcomes of pediatric carbapenem-resistant Klebsiella pneumoniae bloodstream infections in a tertiary care center.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Prevalence and molecular typing of carbapenem-resistant Enterobacterales in a secondary-care hospital in Jazan region, Saudi Arabia.New microbes and new infections · 2026Article
- Risk-Stratified Effectiveness of Cephamycins Versus Carbapenems for ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026Review
- Analytical and Clinical Evaluation of a Fully Automated Direct-from-Whole-Blood Multiplex PCR Assay Using Large-Volume Reverse Elution for Rapid Bloodstream Infection Diagnosis.Antibiotics (Basel, Switzerland) · 2026Article
- Aircraft Wastewater as a Sentinel for Transboundary Antimicrobial Resistance: An Integrated Genomic Approach.Microorganisms · 2026Article
- Contributions of persisters and the Eagle effect to survival ofMicrobiology spectrum · 2026Article
- Chelate-conjugated β-lactams resensitize metallo-β-lactamase IMP-1-producing gram-negative bacteria against carbapenem antibiotics.Microbiology spectrum · 2026Article
- Pandemic-associated shifts in microbial ecology and antimicrobial resistance in a high-volume liver transplant intensive care unit: a 10-year surveillance study.Infection prevention in practice · 2026Article
- Dynamical-nonequilibrium alanine scanning for identifying allosteric positions in proteins.Biophysical journal · 2026Article
- Rectal Surveillance for Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Prevalence and genotypic distribution of virulence factor genes and antibiotic susceptibility profiles in clinicalMicrobiology spectrum · 2026Article
- Clinical Emergence and Genomic Characterization of Aztreonam-Avibactam-ResistantAntibiotics (Basel, Switzerland) · 2026Article
804 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Carbapenem-resistant Enterobacteriaceae (CRE) are a serious public health threat. Infections due to these organisms are associated with significant morbidity and mortality. Mechanisms of drug resistance in gram-negative bacteria (GNB) are numerous; β-lactamase genes carried on mobile genetic elements are a key mechanism for the rapid spread of antibiotic-resistant GNB worldwide. Transmissible carbapenem-resistance in Enterobacteriaceae has been recognized for the last 2 decades, but global dissemination of carbapenemase-producing Enterobacteriaceae (CPE) is a more recent problem that, once initiated, has been occurring at an alarming pace. In this article, we discuss the evolution of CRE, with a focus on the epidemiology of the CPE pandemic; review risk factors for colonization and infection with the most common transmissible CPE worldwide, Klebsiella pneumoniae carbapenemase-producing K. pneumoniae; and present strategies used to halt the striking spread of these deadly pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.